{{Drugbox
| verifiedrevid = 470473641
| IUPAC_name = 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione
| image = Sulfinpyrazone.svg
<!--Clinical data-->
| tradename = Apo-sulfinpyrazone
| Drugs.com = {{drugs.com|monograph|sulfinpyrazone}}
| MedlinePlus = a682339
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =  
| routes_of_administration = oral intravenous
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 98–99%
| metabolism = hepatic
| elimination_half-life =  
| excretion = renal
<!--Identifiers-->
| IUPHAR_ligand = 5826
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 57-96-5
| ATC_prefix = M04
| ATC_suffix = AB02
| ATC_supplemental =  
| PubChem = 5342
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01138
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5149
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = V6OFU47K3W
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00449
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 9342
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 832
<!--Chemical data-->
| C=23 | H=20 | N=2 | O=3 | S=1
| molecular_weight = 404.48 g/mol
| smiles = O=C2N(c1ccccc1)N(C(=O)C2CCS(=O)c3ccccc3)c4ccccc4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MBGGBVCUIVRRBF-UHFFFAOYSA-N
}}

'''Sulfinpyrazone''' is a [[uricosuric]] [[medication]] used to treat [[gout]].  It also sometimes is used to reduce [[platelet]] aggregation by inhibiting [[degranulation]] of platelets which reduces the release of [[Adenosine diphosphate|ADP]] and [[thromboxane]]. 

Like other uricosurics, sulfinpyrazone works by competitively inhibiting [[uric acid]] reabsorption in the [[proximal tubule]] of the [[kidney]].

==Contraindications==
Sulfinpyrazone must not be used in persons with [[renal impairment]] or a history of uric acid kidney stones.<ref name="pmid16740561">{{cite journal |author=Underwood M |title=Diagnosis and management of gout |journal=BMJ |volume=332 |issue=7553 |pages=1315–9 |date=June 2006 |pmid=16740561 |pmc=1473078 |doi=10.1136/bmj.332.7553.1315 |url=}}</ref>

==References==
{{reflist}}

{{Anti-inflammatory and antirheumatic products}}
{{Antigout preparations}}

[[Category:Antigout agents]]
[[Category:Pyrazolidindiones]]


{{musculoskeletal-drug-stub}}